Bridging update edited by Dr Alex Spyropoulos and Dr Marc Cohen covering the use of heparin as bridging therapy when long-term oral anticoagulants are interrupted for an elective procedure or surgery, generated from a monograph on antithrombotic therapy in cardiovascular patients.
This activity has been developed for pharmacists and/or clinical pharmacists, and other health care professionals who treat the 3 main groups of patients affected by bridging therapy: patients with atrial fibrillation, patients with mechanical heart valves, and patients with previous venous thromboembolism.
This program is supported by an educational grant from sanofi-aventis U.S. |